Acute Myeloid Leukemia: The Future Is Bright
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (5 December 2023) | Viewed by 30581
Special Issue Editors
Interests: acute promyelocytic leukemia; acute myeloid leukemia; childhood cancer
Special Issue Information
Dear Colleagues,
The knowledge regarding acute myeloid leukemia (AML) in adults, adolescents and children is rapidly advancing. The extensive characterization of AML cells is now leading to the introduction of tailored therapy, based on a risk group stratified approach, and targeted therapies. Improvements in monitoring measurable residual disease during treatment allow further tailored therapy, while such monitoring following treatment enables pre-emptive treatment of molecular relapses, with acute promyelocytic leukemia as the stimulating example. Moreover, the arsenal of strikingly effective antileukemic drugs is also rapidly expanding, and novel treatment modalities are on the horizon. Together with the improvements in supportive care, the future is bright for all those involved in the care of patients with AML, whether old or young, whether strong or fragile.
Prof. Dr. Gertjan Kaspers
Dr. Kapil Saxena
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- risk group classification
- measurable residual disease
- molecular characterization
- FLT3-ITD
- IDH1/2 mutations
- FLT3 inhibitors
- MEK inhibitors
- gemtuzumab ozogamicin
- supportive care
- acute promyelocytic leukemia
- IDH1/2 inhibitors
- Allogeneic stem cell transplantation
- CAR T-cell therapy
- Immunotherapy